|
1
|
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
|
Ophthalmology
|
2010
|
10.28
|
|
2
|
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
|
N Engl J Med
|
2015
|
7.08
|
|
3
|
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
|
Ophthalmology
|
2011
|
4.15
|
|
4
|
Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial.
|
JAMA Ophthalmol
|
2015
|
2.12
|
|
5
|
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
|
Arch Ophthalmol
|
2009
|
2.06
|
|
6
|
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
|
Ophthalmology
|
2016
|
2.04
|
|
7
|
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
|
Retina
|
2015
|
1.99
|
|
8
|
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy.
|
Am J Ophthalmol
|
2008
|
1.87
|
|
9
|
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.
|
Arch Ophthalmol
|
2009
|
1.72
|
|
10
|
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema.
|
Ophthalmology
|
2008
|
1.60
|
|
11
|
Diabetic macular edema: what is focal and what is diffuse?
|
Am J Ophthalmol
|
2008
|
1.47
|
|
12
|
Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
|
JAMA Ophthalmol
|
2016
|
1.47
|
|
13
|
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.
|
Arch Ophthalmol
|
2012
|
1.47
|
|
14
|
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
|
JAMA Ophthalmol
|
2016
|
1.44
|
|
15
|
A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features.
|
Retina
|
2008
|
1.43
|
|
16
|
A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research.
|
Ophthalmology
|
2010
|
1.34
|
|
17
|
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
|
Ophthalmology
|
2014
|
1.30
|
|
18
|
Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study.
|
Ophthalmology
|
2007
|
1.25
|
|
19
|
Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography.
|
Invest Ophthalmol Vis Sci
|
2012
|
1.17
|
|
20
|
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
|
Arch Ophthalmol
|
2009
|
1.13
|
|
21
|
Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.
|
Ophthalmology
|
2010
|
1.13
|
|
22
|
Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics.
|
Arch Ophthalmol
|
2012
|
1.01
|
|
23
|
Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema.
|
Retina
|
2009
|
1.01
|
|
24
|
The course of response to focal/grid photocoagulation for diabetic macular edema.
|
Retina
|
2009
|
0.99
|
|
25
|
Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetes.
|
Ophthalmology
|
2010
|
0.94
|
|
26
|
Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
|
JAMA Ophthalmol
|
2013
|
0.91
|
|
27
|
Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.
|
Invest Ophthalmol Vis Sci
|
2011
|
0.89
|
|
28
|
Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables.
|
Retina
|
2009
|
0.88
|
|
29
|
Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema.
|
Retina
|
2011
|
0.88
|
|
30
|
Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.
|
JAMA Ophthalmol
|
2014
|
0.85
|
|
31
|
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
|
JAMA Ophthalmol
|
2016
|
0.82
|
|
32
|
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
|
Am J Ophthalmol
|
2016
|
0.81
|
|
33
|
Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network.
|
Retina
|
2013
|
0.81
|
|
34
|
Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial.
|
Retina
|
2010
|
0.80
|
|
35
|
Topical nepafenec in eyes with noncentral diabetic macular edema.
|
Retina
|
2015
|
0.80
|
|
36
|
Evaluation of visual acuity measurements after autorefraction vs manual refraction in eyes with and without diabetic macular edema.
|
Arch Ophthalmol
|
2011
|
0.79
|
|
37
|
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
|
JAMA Ophthalmol
|
2016
|
0.78
|
|
38
|
Evaluation of masking study participants to intravitreal injections in a randomized clinical trial.
|
Arch Ophthalmol
|
2012
|
0.75
|
|
39
|
Effects of dilation on electronic-ETDRS visual acuity in diabetic patients.
|
Invest Ophthalmol Vis Sci
|
2008
|
0.75
|
|
40
|
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
|
Am J Ophthalmol
|
2016
|
0.75
|
|
41
|
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
|
JAMA Ophthalmol
|
2017
|
0.75
|
|
42
|
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
|
Ophthalmology
|
2017
|
0.75
|
|
43
|
Reply.
|
Am J Ophthalmol
|
2017
|
0.75
|
|
44
|
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
|
JAMA Ophthalmol
|
2017
|
0.75
|
|
45
|
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
|
JAMA Ophthalmol
|
2017
|
0.75
|
|
46
|
Elimination of Topical Antibiotics for Intravitreous Injections and the Importance of Using Povidone-Iodine: Update From the Diabetic Retinopathy Clinical Research Network.
|
JAMA Ophthalmol
|
2016
|
0.75
|